TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12892329

Group type: EXPERIMENTAL
Intervention: Electrical impedance measurement over BCC lesions (19 lesions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrical impedance measurement over benign lesions (11 lesions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrical impedance measurement over normal skin (24 patients)
Number of subjects: 24
Study: 10368993

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (H2-RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 0
Study: 8813472

Group type: EXPERIMENTAL
Intervention: [111In‐DTPA-D-Phe1]octreotide (OCT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional imaging techniques (CON)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: OCT radionuclide therapy
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 350
Study: 2002132

Group type: EXPERIMENTAL
Intervention: Together group (patients attended the program with their spouses)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Alone group (patients participated by themselves)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Together group (women)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Alone group (men)
Number of subjects: 49
Study: 6397178

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for one month
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acarbose 100-400 mg/day for six months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 18
Study: 31108379

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) combined with medication (n = 92)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Medication alone (n = 75)
Number of subjects: 167
Study: 30202186

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 394
Study: 27510285

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (10,600 nm, power 25 W) - 3 sessions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-dose UVA-1 phototherapy (30 J/cm2, 340-400 nm) - 30 sessions
Number of subjects: 17
Study: 25415157

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 200

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 200
Study: 22309796

Group type: EXPERIMENTAL
Intervention: Culturally-appropriate family-based interventions developed through community collaboration; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement strategies for participants to enhance motivation for behavior changes after brief programs; specific details not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of behavior changes; specific methods not mentioned.
Number of subjects: 0
Study: 20932272

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 101
Study: 17659972

Group type: EXPERIMENTAL
Intervention: Long-term treatment (continue steroids once daily for 12 months)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Short-term treatment (stop topical steroid treatment)
Number of subjects: 406
Study: 15915612

Group type: EXPERIMENTAL
Intervention: Multi-component health assessment
Number of subjects: 620
Study: 11902625

Group type: EXPERIMENTAL
Intervention: Fearfully attached individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoccupied and dismissive individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insecurely attached individuals
Number of subjects: 0
Study: 10102462

Group type: EXPERIMENTAL
Intervention: Fish diet alone (3.6 g omega3 fatty acids/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moderate exercise alone (55‐65% VO2max)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination of fish diet and moderate exercise
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fish diet alone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (low‐fat diet without fish and exercise)
Number of subjects: 55
Study: 7597630

Group type: EXPERIMENTAL
Intervention: Titaniumtetrafluoride solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 30
Study: 2185664

Group type: EXPERIMENTAL
Intervention: Protein refeeding (80 g protein)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate refeeding (80 g carbohydrate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prolonged fasting
Number of subjects: 10
Study: 696985

Group type: EXPERIMENTAL
Intervention: Beta2-sympathomimetic (ritodrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30925861

Group type: EXPERIMENTAL
Intervention: Multiple mediator analysis for trans-eQTLs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mediation effect (TME) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Component-wise mediation effects (CME) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediation analysis with multiple mediators
Number of subjects: 0
Study: 28434157

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 1007
Study: 26175097

Group type: EXPERIMENTAL
Intervention: NZBC extract (300 mg day(‐1) CurraNZ™ containing 105 mg anthocyanin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL, 300 mg microcrystalline cellulose M102)
Number of subjects: 14
Study: 24749261

Group type: EXPERIMENTAL
Intervention: Prolonged femoral nerve blockade
Number of subjects: 17

Group type: COMPARATOR
Intervention: Epidural infusion of naropine
Number of subjects: 17
Study: 20532965

Group type: EXPERIMENTAL
Intervention: Knowledge of another person's win in a gamble (first experiment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Knowledge of another person's win acknowledged as fortuitous (second experiment)
Number of subjects: 60
Study: 19726588

Group type: EXPERIMENTAL
Intervention: Whole-grain intake (highest quartile)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Cereal fiber intake (highest quartile)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Refined grain intake
Number of subjects: 434

Group type: COMPARATOR
Intervention: Total fiber, vegetable or fruit fiber intake
Number of subjects: 434
Study: 17023088

Group type: EXPERIMENTAL
Intervention: Viscous fiber-containing nutrition bars (VF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Commercial nutrition control bars (CH)
Number of subjects: 99
Study: 15482401

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ + AS)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 308
Study: 11572027

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch (pouch group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis (straight group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 9757987

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (25 microg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7521832

Group type: EXPERIMENTAL
Intervention: Emergency treatment of seizures and aggressive treatment of fever
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further evaluation including neuroimaging, electroencephalogram, and developmental assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with an antiepileptic drug
Number of subjects: 0
Study: 2844494

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conversion enzyme inhibitor
Number of subjects: 7
Study: 29462158

Group type: EXPERIMENTAL
Intervention: 600 mg/day DHA (from algal oil) for 16 weeks
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo: taste/color matched corn/soybean oil for 16 weeks
Number of subjects: 376
Study: 28267152

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26448371

Group type: EXPERIMENTAL
Intervention: High pressure irrigation (>20 psi)
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Low pressure irrigation (5 to 10 psi)
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Very low pressure irrigation (1 to 2 psi)
Number of subjects: 2447

Group type: EXPERIMENTAL
Intervention: Castile soap irrigation
Number of subjects: 2447

Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 2447
Study: 24245738

Group type: EXPERIMENTAL
Intervention: Patients with PCAD
Number of subjects: 57

Group type: COMPARATOR
Intervention: Controls without CAD
Number of subjects: 57
Study: 21145198

Group type: EXPERIMENTAL
Intervention: HIV Symptom Management Self-Efficacy for Women Scale (HSM-SEWS)
Number of subjects: 89
Study: 17610294

Group type: EXPERIMENTAL
Intervention: Fourier-based adaptive Neyman test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wavelet-based thresholding test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional linear regression models (FLRMs)
Number of subjects: 0
Study: 16835968

Group type: EXPERIMENTAL
Intervention: DVd regimen with thalidomide (50 mg/d orally, increased to a maximum of 400 mg/d)
Number of subjects: 102

Group type: COMPARATOR
Intervention: DVd regimen alone
Number of subjects: 102
Study: 12639763

Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine oestrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 47
Study: 10928223

Group type: EXPERIMENTAL
Intervention: Daily 2.5 mg risedronate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cyclical 15 mg risedronate (2 out of 12 weeks)
Number of subjects: 120
Study: 8959812

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study: 1533165

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (TEA) with bupivacaine 0.375% plus sufentanil 1:200,000 (5 micrograms/mL) combined with general anesthesia (midazolam/N2O)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General anesthesia (GA) with midazolam and sufentanil
Number of subjects: 54
Study: 2862196

Group type: EXPERIMENTAL
Intervention: Cannulae with bacteria-retaining filters
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cannulae without bacteria-retaining filters
Number of subjects: 209
Study: 30567457

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 5553

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 5553

Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 5553
Study: 29609070

Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days, and clarithromycin plus metronidazole for the initial 7 days)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Bismuth quadruple therapy (pantoprazole, bismuth, tetracycline, and metronidazole for 14 days)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy
Number of subjects: 352

Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 352
Study: 26890438

Group type: EXPERIMENTAL
Intervention: Gestational Diabetes Mellitus (GDM)
Number of subjects: 763

Group type: COMPARATOR
Intervention: No Gestational Diabetes Mellitus (No GDM)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Composite adverse outcomes
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Superimposed preeclampsia with GDM
Number of subjects: 763

Group type: COMPARATOR
Intervention: Superimposed preeclampsia without GDM
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Superimposed preeclampsia
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Length of stay in neonatal intensive care unit
Number of subjects: 763
Study: 24055515

Group type: EXPERIMENTAL
Intervention: Site-reported duplex ultrasound (DU) scans prior to treatment
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Site-reported duplex ultrasound (DU) scans at 12-month follow-up
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: Doppler angle alignment errors
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: UCL review of prior-to-treatment scans
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: UCL review of follow-up scans
Number of subjects: 1702

Group type: EXPERIMENTAL
Intervention: CAS vs CEA reclassification rates
Number of subjects: 1702
Study: 22057579

Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19288181

Group type: EXPERIMENTAL
Intervention: Resumed anticoagulation
Number of subjects: 608

Group type: COMPARATOR
Intervention: Stopped anticoagulation
Number of subjects: 608

Group type: COMPARATOR
Intervention: Normal D-dimer
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer
Number of subjects: 608
Study: 16962674

Group type: EXPERIMENTAL
Intervention: AV sequential pacing at septum (DDDspt)
Number of subjects: 42

Group type: COMPARATOR
Intervention: AV sequential pacing at RV apex (DDDapx)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atrial pacing (AAI)
Number of subjects: 42
Study: 15876304

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: House dust mite provocations
Number of subjects: 20
Study: 12394665

Group type: EXPERIMENTAL
Intervention: Early active treatment program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Less active training program (control group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 10091909

Group type: EXPERIMENTAL
Intervention: Traditional maximum likelihood logistic method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric logistic method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified (multicenter) and multivariate (multivisit) analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportional odds model
Number of subjects: 0
Study: 8852495

Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura) 2-8 mg once daily or 8 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (Capoten) 25-50 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine (Procardia-XL) 30-60 mg once daily
Number of subjects: 30
Study: 1934433

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia and reperfusion (Hôpital Lariboisière protocol)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia with allopurinol enriched blood reperfusion (Hôpital Broussais protocol)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cold blood cardioplegia with unmodified blood reperfusion (control group)
Number of subjects: 33
Study: 7211735

Group type: EXPERIMENTAL
Intervention: Defined liquid diets
Number of subjects: 10

Group type: COMPARATOR
Intervention: Free-choice diet
Number of subjects: 10
Study: 31004340

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy (alpha-blocker, anti-inflammatory agent, muscle relaxant, short course of antibiotic)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham-ESWT combined with pharmacotherapy
Number of subjects: 31
Study: 31325474

Group type: EXPERIMENTAL
Intervention: Visual food stimuli presented as first targets in a rapid stream of pictures
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Visual food stimuli presented as second targets
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Task irrelevant food distractors
Number of subjects: 103
Study: 28715586

Group type: EXPERIMENTAL
Intervention: Iris-claw intraocular lens (IC‐IOL) implantation
Number of subjects: 390

Group type: COMPARATOR
Intervention: Scleral-fixated posterior chamber intraocular lens (SF‐PCIOL) implantation
Number of subjects: 390
Study: 31149084

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: All neuroleptics
Number of subjects: 113
Study: 23857036

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MIT)
Number of subjects: 36
Study: 22633423

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) containing 500 IU/mL thrombin and synthetic aprotinin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Manual compression (control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 140
Study: 19668789

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) in 2004-2005 cohort
Number of subjects: 243

Group type: COMPARATOR
Intervention: Fibrinolysis in 1999-2000 cohort
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Primary PCI in 2004-2005 cohort
Number of subjects: 243
Study: 17678487

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous carotid angioplasty and stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiplatelet agents (i.e., clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholesterol-lowering agents (i.e., statins)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study: 15130870

Group type: EXPERIMENTAL
Intervention: Predictive (80% cued)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonpredictive (50% cued)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Antipredictive (20% cued)
Number of subjects: 18
Study: 12182769

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 46
Study: 10322740

Group type: EXPERIMENTAL
Intervention: Experimental group (34 patients)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 61
Study: 7647725

Group type: EXPERIMENTAL
Intervention: Pollinex (Bencard)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2796617

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine 10 mg in hyperbaric solution
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0.5% tetracaine 10 mg in isobaric solution
Number of subjects: 102
Study: 356246

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren, 25 mg t.i.d.)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg t.i.d.)
Number of subjects: 109
Study: 31317388

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0
Study: 30315687

Group type: EXPERIMENTAL
Intervention: Laparoscopically guided transversus abdominis plane block (LTAP) with bupivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Port-site local anaesthetic infiltration (LAI) with bupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27781388

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) practices in Turkey
Number of subjects: 66711
Study: 25892170

Group type: EXPERIMENTAL
Intervention: Volitional help sheet (intervention group, n=34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active control condition (n=31)
Number of subjects: 65
Study: 22438297

Group type: EXPERIMENTAL
Intervention: III + ISG
Number of subjects: 31

Group type: COMPARATOR
Intervention: III only
Number of subjects: 31
Study: 20820817

Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg orally twice a day for 28 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 19634958

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Educational control intervention
Number of subjects: 150
Study: 17869297

Group type: EXPERIMENTAL
Intervention: Transurethral resection in saline
Number of subjects: 238

Group type: COMPARATOR
Intervention: Monopolar transurethral prostate resection
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 238
Study: 15231445

Group type: EXPERIMENTAL
Intervention: Major depression (MD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 15
Study: 11509491

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine patch (14 patients)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transdermal placebo (12 patients)
Number of subjects: 26
Study: 9269880

Group type: EXPERIMENTAL
Intervention: Positive reinforcement for decreases in high-preference sedentary activity
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Punishment for high-preference sedentary activity
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Access to high-preference sedentary activity restricted
Number of subjects: 34

Group type: COMPARATOR
Intervention: No contingencies on activity (control group)
Number of subjects: 34
Study: 8111799

Group type: EXPERIMENTAL
Intervention: Quinapril 10.0, 20.0, or 40.0 mg, or 20 mg plus 12.5 mg hydrochlorothiazide (HCTZ) given once daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 40 mg quinapril daily or 20 mg quinapril plus 12.5 mg HCTZ daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 256
Study: 3739802

Group type: EXPERIMENTAL
Intervention: Self-control skills intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo condition (discussion-oriented intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 30908867

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (Fitbit Zip, step goals, 1 phone call/month for 6 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard physical therapy (control group)
Number of subjects: 43